HomeAI · summaries
Storia in 4 fonti
J&J multiple myeloma drug gains edge in earlier stage disease
The latest results studying Talvey in combination with Darzalex Faspro support J&J’s efforts to expand the immunotherapy's use.
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
medpagetoday.com
Talquetamab Regimens Boost Survival in Multiple Myeloma
'Combinations represent additional options for early-line treatment,' researcher says
- ·
fiercepharma.com
EHA: J&J sharpens myeloma edge as Talvey, Darzalex Faspro combo proves its worth in earlier disease stage
In a plenary session at the 2026 European Hematology Association (EHA) annual meeting in Stockholm, Johnson & Johnson brought to the world stage a reminder of its status as a…
